The use of weight management drugs in the UK has seen a significant surge, particularly with the recent rise in prescriptions for popular medications like Ozempic, Mounjaro, and Wegovy. According to reports, nearly three million prescriptions were issued in England last year, sharply increasing from 1.4 million in 2022-2023 to approximately 2.7 million last year. This trend highlights a growing reliance on these medications as both weight loss aids and treatments for type 2 diabetes. Mounjaro, in particular, has emerged as a leading contender in this category, earning the nickname "King Kong" of weight loss injections due to its considerable efficacy and rising popularity.

The increased usage of Mounjaro, or tirzepatide, has not only boosted prescription numbers but also resulted in a dramatic rise in expenditure—£269 million spent by the NHS on these jabs last year alone, reflecting an overall increase in spending of £93.1 million across various dosages. Most of the prescribed medications have gone to patients diagnosed with type 2 diabetes, yet a notable number are also accessing these drugs through private prescriptions. This suggests a broader acceptance and implementation of pharmacological interventions in managing weight and related health issues.

In November 2023, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) officially authorised the use of Mounjaro for weight management, conditional upon a patient’s body mass index (BMI) and associated weight-related health concerns. Specifically, this approval targets adults with a BMI of 30 or more (indicating obesity) or those with a BMI ranging from 27 to 30 who also suffer from conditions like prediabetes or high cholesterol. Mounjaro works by modulating appetite, effectively helping users feel satiated while minimising cravings. The medicine is administered through weekly injections and is intended to be coupled with a balanced diet and increased physical activity.

Building on the MHRA's endorsement, the National Institute for Health and Care Excellence (NICE) in June 2024 recommended Mounjaro for broader use in treating obesity, particularly in individuals with a BMI of 35 or higher who also face additional health risks. Clinical research indicates that Mounjaro can enable users to lose nearly 22.5% of their body weight over a 72-week period, outpacing the results associated with semaglutide (Wegovy), which typically produces a 16% weight loss.

Despite these encouraging developments, new hurdles have arisen. In December 2024, the NHS announced a phased rollout for Mounjaro, initially limiting access to around 220,000 patients in England. This cautious strategy aims to avoid overwhelming healthcare resources while ensuring a systematic and equitable distribution of the drug to those with the greatest clinical need. The phased approach has drawn criticism from patient advocacy groups, who express concern over the prolonged wait times and the urgency of addressing obesity-related health issues.

As the landscape of weight management medications evolves, Mounjaro represents a pivotal addition to treatment options, promising not only to reshape individual health outcomes but also to alleviate some of the systemic pressures faced by the NHS. The ongoing monitoring of its effects and access will be vital in ensuring its success in the UK healthcare system.

📌 Reference Map:

Source: Noah Wire Services